Category:Disability in the United Kingdom
Category:Disability legislation
Category:Disability law
Category:Fire prevention
Category:Firefighting equipment
Category:Fire protection
Category:Medical regulation in the United Kingdom
Category:Public health in the United Kingdom
Category:Occupational safety and health
Category:Safety codes
Category:Fire codesEfficacy and safety of pregabalin in patients with fibromyalgia.
To assess the efficacy and safety of pregabalin in patients with fibromyalgia syndrome (FMS). The efficacy and safety of pregabalin (at doses of 300 and 600 mg) were evaluated in a randomized, double-blind, placebo-controlled trial of 101 patients with FMS who had a mean duration of disease of 7.8 years. The primary efficacy variable was the reduction from baseline in average daily pain score (average of three 24-hour scores) at the end of week 6. The change in the weekly score was analyzed using a mixed-model analysis of variance. The patients were followed-up for an additional week after completion of the randomized phase. Both doses of pregabalin were significantly more effective than placebo in reducing average daily pain (P = 0.002 and 0.008, respectively), pain upon pressure, and pain upon flexion. Pregabalin at 600 mg/day was significantly more effective than pregabalin at 300 mg/day (P = 0.004). Pregabalin was well tolerated. The most common adverse events were somnolence, dizziness, and nausea. One patient discontinued the study due to dizziness and nausea. Pregabalin at 600 mg/day was effective in reducing pain associated with FMS, and was well tolerated.A pharmacoeconomic analysis of an oral rotavirus vaccine.
An oral rotavirus vaccine has the potential to significantly decrease the annual cost of rotavirus gastroenteritis in the United States by reducing the number of hospitalizations. To model the impact of an oral rotavirus vaccine on health care utilization, cost, and economic outcomes, a decision-analytic Markov model was developed to simulate the natural history of rotavirus infection in children in the United States. The model included the 2 main types of rotavirus gastroenteritis, diarrhea and non-diarrhea, with two strategies (immunization and no immunization) and three efficacy levels (80%, 60%, and 40%) based on the published efficacy trial ac619d1d87
Related links: